Cerevel Therapeutics

Practice Area: 
Stock Symbol: 
Case Status: 

Ademi LLP is investigating Cerevel (NASDAQ: CERE) for possible breaches of fiduciary duty and other violations of law in its transaction with AbbVie.

In the transaction, Cerevel stockholders are expected to receive only $45.00 per share in cash. The transaction values Cerevel at a total equity value of approximately $8.7 billion The transaction agreement unreasonably limits competing transactions for Cerevel by imposing a significant penalty if Cerevel accepts a competing bid. Cerevel insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Cerevel’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.